These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 15108250)

  • 1. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
    Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
    Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
    Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
    Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
    Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S; Rogge J; Weaver L; Schafer DF
    Transplant Proc; 2003 Dec; 35(8):3042-4. PubMed ID: 14697974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
    Rivero-Juárez A; Mira JA; Pérez-Camacho I; Macías J; Camacho A; Neukam K; Torre-Cisneros J; Merchante N; Pineda JA; Rivero A;
    J Antimicrob Chemother; 2011 Jun; 66(6):1351-3. PubMed ID: 21415037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
    Iwai A; Marusawa H; Takada Y; Egawa H; Ikeda K; Nabeshima M; Uemoto S; Chiba T
    J Viral Hepat; 2006 Aug; 13(8):523-31. PubMed ID: 16901282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
    Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.